Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: remove him....

they had enough cash for one year of continuing operations does not mean they were not in a cash crunch; a severe one.

Apparently you think 7 Mil in cash is sufficient for a public company burning though over a million a year for just inhouse administrative operations, and who's whole business model is built on leveraging litigation, including ongoing litigation with multiple concurrent defendants, and based on openended cash payouts to third parties for litigation preparation and infringment prosecution; regardless if any revenues are actually received, from which further contingency payouts would necessary follow, is somehow adequate ?? Perhaps they should have saved some printing ink and left off all those increasingly long warnings and disclaimers in every SEC filing as well. lol.

You point to "Share Buybacks" as proof that there was no need to conserve cash ? LOL, it's likely that we have spent less on Share Buybacks in their window dressing effort to improve Shareholder Equity over the last 3 or 4 years combined, than what we paid to the temporary CEO in any single year alone. Why don't you go back and add up the Buyback costs since 2010 and report to this board so you can prove your point how they had sufficient enough cash for future operations and to be able fund meaningful Share Buybacks ? I think in this last quarter the amount of shares bought back equated to 1/10th of 1% of the outstanding; the BOD members are paid more than that equilivent cash amount each and every month. LOL. I don't recommend anyone hold their breath waiting for you. Additionally, as I recall, the company even used the need to cut expenses as a reason for cancelling that inperson SHAM; if you believe they were telling the truth, it sure seems like we had a severe cash situation to me.

You also indicated as proof of no cash crunch that we still had Treasury Stock that was unsold. With 400,000,000+ shares already outstanding, and with so little existing liquity in the stock that avg daily volumes of 200K shares generally does not even support the day's opening price, it just shows that you have absolutely no clue about the implications surrounding public company capitalization. Perhaps you can ask someone to help you understand corporate finance structuring ?

I'll make it very simple in just one example, so you can understand it ... if PTSC was not in a cash crunch they would not have sold PDSG (2012), and, have been in such a distressed situation to do so, that they essentially gave it away in exchange for some percentage of future revenues until April 2015. The only out of pocket costs for the buyer was that they reiumburse us for some recent expenses. We were willing to lose the entire many many millions the BOD poured in to it, just to stop the hemoraging it was causing on our cash position. I think so far PTSC has only received a total of $45,000 in PGDS royalties from the sale.

My last post on this.

Share
New Message
Please login to post a reply